Zocor (Simvastatin)
Brand Names: Zocor
Methodology & AI Transparency ⓘ
Zocor (Simvastatin) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary hmg-coa reductase inhibitor presentation registered by Organon LLC, Zocor supplies active moiety Simvastatin (cross-referenced at /meds/simvastatin) in 10 mg/1 Tablet, Film Coated; 20 mg/1 Tablet, Film Coated (NDC 78206-180, 78206-182; SPL 2025-03-28).
- 2 Real-world patient consensus: Registered under RxNorm 104490 and SPL 2025-03-28, pairing Zocor packaging with active ingredient Simvastatin.
- 3 Typical cash cost range: Public pharmacy ledger: $5.34 low cash benchmark vs. $34.50 chain retail average ($9.7294/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Zocor (Simvastatin)): nausea (12%), headache (10.6%), constipation (6.5%).
Ask our AI Specialists anything about Zocor (Simvastatin)
Zocor (Simvastatin) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary hmg-coa reductase inhibitor presentation registered by Organon LLC, Zocor supplies active moiety Simvastatin (cross-referenced at /meds/simvastatin) in 10 mg/1 Tablet, Film Coated; 20 mg/1 Tablet, Film Coated (NDC 78206-180, 78206-182; SPL 2025-03-28). Clinical prescribing and dispensing guidelines focus on 1 Indications and usage zocor: ® is indicated: To reduce the risk of total mortality by reducing risk of coronary heart.
The active constituent inside Zocor—Simvastatin—functions as a targeted hmg-coa reductase inhibitor agent involving CYP3A4/OATP1B1 clearance pathways. While therapeutic target engagement mirrors generic Simvastatin, Zocor (registered by Organon LLC, SPL 2025-03-28) specifies proprietary packaging (78206-180, 78206-182) and 10 mg/1 Tablet, Film Coated; 20 mg/1 Tablet, Film Coated quality controls alongside a $9.7294/unit NADAC acquisition baseline.
Following administration (10 mg/1 Tablet, Film Coated), Zocor (Simvastatin) achieves Estimated 53%–65% oral systemic absorption for Zocor (Simvastatin) bioavailability and peak plasma concentration (tmax) reached 1–3 hours post-dose for zocor (simvastatin) onset, governed by a Approximately 6–18 hours terminal plasma half-life for Zocor (Simvastatin) terminal half-life through hepatic oxidation via cyp3a4/oatp1b1 followed by renal and biliary excretion of zocor (simvastatin) metabolites.
Before initiating Zocor (Simvastatin) at 10 mg/1 Tablet, Film Coated, clinical safety checklists rule out documented intolerance or hypersensitivity reaction involving simvastatin (hmg-coa reductase inhibitor); concurrent restricted medications flagged in section 4/7 of the zocor (simvastatin) dailymed monograph (104490). Logged tolerability patterns center on nausea (12% of reports), headache (10.6% of reports), nasopharyngitis (8.7% of reports).
Concurrent Zocor (Simvastatin) exposure alters anticoagulant pharmacodynamics, requiring closer hemorrhagic surveillance.
Intestinal or renal P-glycoprotein competition with Zocor (Simvastatin) can increase systemic glycoside exposure.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Simvastatin (hmg-coa reductase inhibitor)
- Concurrent restricted medications flagged in Section 4/7 of the Zocor (Simvastatin) DailyMed monograph (104490)
Logged Side-Effect Incidence (5 Reports)
Zocor (Simvastatin) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zocor (Simvastatin))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes and high: What a 1,229-Participant Study Found Ezetimibe/simvastatin provided additional lipid-modifying benefits over atorvastatin single-drug treatment at the recommended usual starting and next highest doses in patients with type 2 diabetes. Mayo Clinic proceedings • 2006-12-15 • Randomized Controlled Trial | N = 1,229 | 96/100 | PMID 17165637 ↗ |
| New Insights on Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus: What a 2,959-Participant Study Found Ezetimibe/simvastatin was more effective than rosuvastatin in LDL-C lowering, and provided greater or comparable improvements in other lipid measures and hsCRP at the approved usual starting, next highest, and maximum doses in... Current medical research and opinion • 2006-10-15 • Randomized Controlled Trial | N = 2,959 | 96/100 | PMID 17022864 ↗ |
| New Insights on Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with: What a 314-Participant Study Found EZE/SIMVA 10/20 mg produced greater improvements in LDL-C, total cholesterol, non-HDL-C and apoB with a similar safety profile as for ROSUVA 10 mg. International journal of clinical practice • 2009-04-15 • Randomized Controlled Trial | N = 314 | 93/100 | PMID 19222610 ↗ |
| New Insights on Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and: What a 263-Participant Study Found Approximately 45% of. International journal of clinical practice • 2010-07-15 • Randomized Controlled Trial | N = 263 | 93/100 | PMID 20487050 ↗ |
| New Insights on Real-world benefits and safety of atorvastatin and simvastatin in patients with: What a 1,732-Participant Study Found In both comparator groups a higher proportion of atorvastatin-treated patients reached their NCEP LDL cholesterol goal compared with simvastatin. The American journal of cardiology • 2002-03-15 • Randomized Controlled Trial | N = 1,732 | 90/100 | PMID 11897207 ↗ |
Zocor (Simvastatin) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $9.7294/unit (~$291.88/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $5.34 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $7.50 / mo | View logs ↓ |
Zocor (Simvastatin) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Zocor (Simvastatin) RxNorm Concept ID | 104490 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $9.7294 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $5.34 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 89.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Zocor (Simvastatin) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Zocor (Simvastatin): FDA labeling (2025-03-28, NDC 78206-180), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Zocor (Simvastatin) community threads and patient logs by age, biological sex, dosage, and treatment duration.